0001209191-22-039692.txt : 20220628
0001209191-22-039692.hdr.sgml : 20220628
20220628194804
ACCESSION NUMBER: 0001209191-22-039692
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220624
FILED AS OF DATE: 20220628
DATE AS OF CHANGE: 20220628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PURA VIDA INVESTMENTS, LLC
CENTRAL INDEX KEY: 0001590144
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 221051480
BUSINESS ADDRESS:
STREET 1: 512 W 22ND STREET
STREET 2: 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10011
BUSINESS PHONE: 646-597-6995
MAIL ADDRESS:
STREET 1: 512 W 22ND STREET
STREET 2: 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10011
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kamen Efrem
CENTRAL INDEX KEY: 0001789193
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 221051479
MAIL ADDRESS:
STREET 1: C/O PURA VIDA INVESTMENTS, LLC
STREET 2: 512 W 22ND STREET, 7TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10011
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncocyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: 949-409-7600
MAIL ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20200213
FORMER COMPANY:
FORMER CONFORMED NAME: Oncocyte Corp
DATE OF NAME CHANGE: 20200205
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20150513
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-24
0
0001642380
Oncocyte Corp
OCX
0001590144
PURA VIDA INVESTMENTS, LLC
512 W 22ND STREET
7TH FLOOR
NEW YORK
NY
10011
0
0
1
0
0001789193
Kamen Efrem
C/O PURA VIDA INVESTMENTS, LLC
512 W 22ND STREET, 7TH FLOOR
NEW YORK
NY
10011
0
0
1
0
Common Stock
2022-06-24
4
S
0
10964
1.0514
D
7462643
I
By Pura Vida Master Fund, Ltd.
Common Stock
2022-06-24
4
S
0
35441
1.0269
D
7427202
I
By Pura Vida Master Fund, Ltd.
Common Stock
2022-06-24
4
S
0
12517
1.0514
D
8520146
I
By the Managed Accounts.
Common Stock
2022-06-24
4
S
0
40464
1.0269
D
8479682
I
By the Managed Accounts.
Aggregate number of shares sold on the same date at difference prices.
Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.04 to $1.09, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Securities and Exchange Commission staff (the "Staff), Issuer or any security holder, upon request.
Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.
Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.02 to $1.0475, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request.
Although these sales are matchable transactions to purchases on April 14, 2022 under Section 16(b) of the Securities Exchange Act of 1934, as amended, the sales prices are less than the purchase prices, constituting a loss and, as such, there are no profits to disgorge pursuant to Section 16(b).
/s/ Efrem Kamen, Managing Member of Pura Vida Investments, LLC
2022-06-28
/s/ Efrem Kamen
2022-06-28